Aim7 30mg/15mg/500mg Tablet XR
Marketer
Eris Lifesciences Ltd
Salt Composition
Gliclazide (30mg) + Pioglitazone (15mg) + Metformin (500mg)
Overview Aim7 30mg/15mg/500mg Tablet XR
Diabetaid XR 30mg/15mg/500mg tablets are prescribed for managing type 2 diabetes. This medication assists adults in regulating blood glucose. Diabetaid XR should be ingested with meals, ideally at the same time daily. Dosage is determined by your physician and may be adjusted based on your blood sugar readings. Consistent use is vital; discontinuation without medical consultation can lead to elevated blood sugar, increasing the risk of kidney complications, vision loss, neuropathy, and limb amputation. Remember, this medication complements a comprehensive diabetes management plan including diet, exercise, and weight management as recommended by your doctor. Lifestyle choices significantly impact diabetes control. Hypoglycemia (low blood sugar) is a frequent side effect, characterized by sweating, dizziness, and headaches. Regular meals and readily available glucose sources (e.g., sugary snacks or juice) are crucial for prevention. Alcohol consumption elevates hypoglycemia risk and should be limited. Additional potential side effects include nausea, altered taste, diarrhea, abdominal discomfort, cephalalgia, edema, blurred vision, fractures, and upper respiratory infections. Weight gain is also possible. This medication is contraindicated for type 1 diabetes, diabetic ketoacidosis, and severe hepatic or renal impairment. Individuals with a history of cardiovascular disease should inform their physician before starting treatment. Pregnant or lactating individuals require medical consultation prior to use. Regular blood glucose monitoring and blood tests to assess blood cell counts and liver function are recommended.
Primary Ingredients of Aim7 30mg/15mg/500mg Tablet XR
No text provided to rephrase.
Uses of Aim7 30mg/15mg/500mg Tablet XR
Managing Type 2 Diabetes
Major Benefits of Aim7 30mg/15mg/500mg Tablet XR:
Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the Aim7 30mg/15mg/500mg Tablet XR whole; do not break, crush, or chew it. Administer this medication with a meal.
Common Side effects of Aim7 30mg/15mg/500mg Tablet XR:
- Hypoglycemia (low blood glucose level)
- Dizziness
- Headache
- Nausea
- Vomiting
- Diarrhea
- Flatulence
- Upper respiratory tract infection
- Bronchitis (inflammation of the airways)
- Anemia (low number of red blood cells)
- Edema (swelling)
How to use Aim7 30mg/15mg/500mg Tablet XR:
Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the Aim7 30mg/15mg/500mg Extended-Release tablet whole; do not crush, chew, or divide it. Administer this medication with a meal.
How Aim7 30mg/15mg/500mg Tablet XR works:
Aim7 XR tablets (30mg/15mg/500mg) combine gliclazide, pioglitazone, and metformin—three distinct antidiabetic agents—to optimize blood glucose management when monotherapy or dual therapy proves insufficient. Gliclazide, a sulfonylurea, stimulates pancreatic insulin secretion, reducing blood glucose levels. Pioglitazone, a thiazolidinedione, enhances insulin sensitivity. Metformin, a biguanide, acts by decreasing hepatic glucose production, slowing intestinal glucose absorption, and improving insulin responsiveness.
SAFETY ADVICE
AlcoholUNSAFE
Concurrent alcohol use with Aim7 30mg/15mg/500mg XR tablets is inadvisable.
PregnancyCONSULT YOUR DOCTOR
The extended-release Aim7 30mg/15mg/500mg tablet might pose risks during pregnancy. While human data is scarce, animal research indicates potential harm to the fetus. A physician will assess the potential advantages against possible dangers prior to prescribing. Seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
The extended-release Aim7 30mg/15mg/500mg tablet is likely unsuitable for breastfeeding mothers. Available human data indicate potential transfer to breast milk, posing a possible risk to the infant.
DrivingCAUTION
Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.
KidneyUNSAFE
The extended-release Aim7 30mg/15mg/500mg tablet is likely to pose risks for individuals with impaired kidney function and its use should be avoided. Medical advice is recommended.
LiverUNSAFE
Patients with liver impairment should likely avoid Aim7 30mg/15mg/500mg Tablet XR, as its use may be hazardous. Medical advice is recommended.
What if you forget to take Aim7 30mg/15mg/500mg Tablet XR :
Should you forget a dose of Aim7 30mg/15mg/500mg Extended-Release Tablet, administer it promptly. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Aim7 30mg/15mg/500mg Tablet XR
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Diabetes Management |




